Citations

Clear

4439 citation(s) found for "Lee, E".

Machine learning-based prediction of hypotension following emergency intubation
Sujanyal, Saurabh Ashok , Omercikoglu, Elcin , Alazab, Heba, Handral, Megha, LEE, JIEUN , Saunders, Hollie , Arunachalam, S P , Sujanyal, Saurabh , Alazab, Heba, Handral, Megha Sasidhar, Arunachalam, Shivaram P. , Helgeson, Scott A.

Mayo Clinic

BMJ Innovations | September 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: bmjinnov-2026-001625

10.1136/bmjinnov-2026-001625 Get It

Introduction Post-intubation hypotension (PIH) is a frequent complication of emergency endotracheal intubation and is associated with increased mortality. Early identification of high-risk patients remains challenging, and existing prediction tools demonstrate moderate accuracy. Objective We aim to identify predictors of PIH and develop machine learning models for pre-intubation risk stratification. Methods We conducted a multicentre retrospective study across 3 Mayo Clinic hospitals, including 600 adults undergoing urgent intubation in the intensive care unit. PIH was defined by mean arterial pressure<65 mm Hg, systolic blood pressure (SBP)<80 mm Hg or ≥40% decline or vasopressor initiation/escalation within 30 min. Three model frameworks were developed: Shock Indices (SIs), Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA), incorporating demographic, haemodynamic, laboratory and sedation variables. Various machine learning algorithms were applied to analyse the three models. Results PIH occurred in 46% of patients included in the study. In the SIs model, stepwise logistic regression achieved an area under the curve (AUC) of 0.76. The APACHE II framework showed the strongest performance, with random forest achieving an ROC AUC of 0.82 and the ensemble model demonstrating the highest overall discrimination (Receiver operator Curve [ROC] AUC 0.83) with favourable accuracy and F1 metrics. The SOFA framework showed moderate performance, with an ensemble ROC AUC of 0.73. Key predictors included pre-intubation vasopressor use, SBP, platelet count and haematological parameters. Conclusions Machine learning models using routinely available pre-intubation data showed potential to predict PIH in this retrospective proof-of-concept study. These findings support further development of anticipatory artificial intelligence-driven risk stratification in critical care, but the models should not be considered ready for bedside implementation until they undergo prospective validation in larger, independent and more diverse cohorts.
Prognostic Value of Artificial Intelligence ECG–Derived Diastolic Function in Surgical Aortic Valve Replacement
Sawma, Tedy , Schaff, Hartzell V. , Danesh, Sina , Arghami, Arman , Lee, Eunjung , Aslahishahri, Masoomeh, Stulak, John, Greason, Kevin L. , Dearani, Joseph A. , López-Jiménez, Francisco , Friedman, Paul A. , Oh, Jae K. , Dearani, Joseph A. , Greason, Kevin , Sabbah, Michael S. , Attia, Zachi I , Oh, Jae K. , Crestanello, Juan A , Lopez-Jimenez, Francisco , Arghami, Arman , Schaff, Hartzell , Stulak, John M., Pislaru, Sorin V. , Attia, Zachi I. , Crestanello, Juan A.

Mayo Clinic

Journal of the American Heart Association | August 31, 2026 | Volume: 15 | Issue: 19 | Pages: No page available

10.1161/jaha.126.050492 | PMID 42669926 Get It

Background Diastolic dysfunction is common in patients with aortic stenosis and may influence outcomes following surgical aortic valve replacement. We aimed to examine the association of preoperative artificial intelligence (AI)‐generated diastolic function grades with early and late outcomes following aortic valve replacement and how postoperative progression influence prognosis. Methods We identified 5503 patients undergoing aortic valve replacement between 2000 and 2023. Diastolic function was assessed using a validated deep‐learning AI model applied to 12‐lead ECGs done preoperatively and on postoperative follow‐up. Diastolic grades were classified by AI into Grades 1 to 3. Longitudinal trend analyses and multivariable regression models were used to assess study end points. Results Among 5503 patients (mean age 72.4±10.8 years; 39% female), higher AI ECG diastolic grades were associated with greater comorbidity burden, including diabetes, renal disease, and heart failure. AI ECG diastolic Grade 3 was independently associated with higher in‐hospital mortality (odds ratio, 2.5; P =0.007) and other complications. At 5‐year follow‐up, patients with Grade 3 showed the least improvement in diastolic function by both ECG and echocardiography. Grades 2 and 3 diastolic function at baseline were independently associated with increased late mortality (hazard ratio, 1.3 and 2.45, respectively; both P <0.001). Additionally, lack of improvement in AI ECG diastolic grade by 1 year was also independently associated with late mortality. Conclusions AI ECG–derived diastolic function grades strongly correlates with early complications and long‐term mortality and diastolic progression after aortic valve replacement. AI ECG provides a powerful, noninvasive tool for risk stratification and longitudinal monitoring of patients with aortic stenosis.
Artificial Intelligence–Enabled Acquisition and Interpretation for Screening Aortic Stenosis
Naser, Jwan A., Kane, Conor J. , Kovac, Jude L., Greason, Christie, Killalea, Méabh M., Gulati, Mayari A., Jackson, John I. , Borgeson, Jordan, Schonfeld, Daniel A., Crestanello, Maria M., Zacher, Jessica, Çamalan, Seda , Thaden, Jeremy J. , Anand, Vidhu, Nkomo, Vuyisile T., Padang, Ratnasari , Chao, Chieh-Ju, Pellikka, Patricia A., Lopez-Jimenez, Francisco, Friedman, Paul A., Oh, Jae K., Kane, Garvan C., Attia, Zachi I., Pislaru, Sorin V., Bird, Jared G., Tsaban, Gal, Malins, Jeffrey G. , Poterucha, Timothy J. , Lee, Eunjung , Naser, Jwan A. , Kovac, Jude Laures, Greason, Christie, Killalea, Méabh Maria, Gulati, Mayari A., Borgeson, Jordan, Schonfeld, Daniel Andres, Anisuzzaman, DM , Crestanello, Maria Mercedes, Anand, Vidhu , Nkomo, Vuyisile T. , Poterucha, Timothy Joseph , Chao, Chieh‐Ju , Pellikka, Patricia A. , López-Jiménez, Francisco , Friedman, Paul A. , Oh, Jae K. , Kane, Garvan C. , Attia, Zachi I. , Pislaru, Sorin V. , Tsaban, Gal

Mayo Clinic

JAMA Cardiology | August 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamacardio.2026.3829 | PMID 42661496 Get It

Importance Timely identification of aortic stenosis (AS) is essential for appropriate clinical management, yet screening remains limited by dependence on comprehensive echocardiography and trained imaging personnel. Objective To develop and validate a deep learning algorithm for detection of moderate or greater AS and prospectively evaluate its performance using artificial intelligence (AI)–guided focused cardiac ultrasound (FoCUS) acquired by novice operators. Design, Setting, and Participants This diagnostic study included retrospective algorithm development and validation and prospective evaluation of AI-guided FoCUS across Mayo Clinic sites in the Midwest, Arizona, and Florida. The model was developed using 6753 patients and evaluated in internal validation (n = 852), internal test (n = 844), and validation (n = 1912) cohorts. Performance was assessed on FoCUS acquired by experienced sonographers (n = 602) and prospectively by novice operators (n = 1302). The retrospective model development and validation cohorts comprised studies performed from January 2005 through September 2022. Prospective study was conducted in 2 enrollment periods from June to August 2024 and from June to September 2025. Participants from both periods were combined to comprise the final prospective cohort. Exposure AI-guided FoCUS acquisition and automated deep learning–based assessment for detection of moderate or greater AS. Main Outcomes and Measures Detection of moderate or greater AS. Performance was assessed using area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, and positive predictive value. Results The model demonstrated excellent discrimination in the internal test cohort (AUROC, 0.99; 95% CI, 0.98-1.00) and geographically distinct validation cohorts in Arizona (AUROC, 0.99; 95% CI, 0.97-1.00) and Florida (AUROC, 0.99; 95% CI, 0.96-1.00). Among FoCUS examinations acquired by experienced sonographers, sensitivity was 95% (95% CI, 82-99) and specificity was 97% (95% CI, 95-98). In the prospective novice-operator cohort, 1258 of 1302 examinations (96.6%) were suitable for automated analysis. Sensitivity was 93% (95% CI, 82-99) and specificity was 96% (95% CI, 95-97). Expert review of AI-positive and uninterpretable examinations increased the positive predictive value from 49.4% to 91.1%, with sensitivity of 85.4%. Conclusions and Relevance A deep learning algorithm accurately detected moderate or greater AS across validation cohorts in this study. In prospective evaluation, novice operators were able to acquire AI-guided FoCUS examinations that enabled accurate detection of moderate or greater AS. These findings support a scalable strategy that may expand access to AS detection in settings with limited echocardiography resources.
Enterochromaffin cells as a cellular integration hub for cooperative microbial signaling to modulate gut serotonin and motility
Xiao, Yang , Till, Lisa , Gupta, Yash, Mercado‐Perez, Arnaldo , Bhagwate, Aditya V., Bellampalli, Shreya S. , Stark, Alejandro , Sekhon, Prabhjot K., Singh, Vaidhvi , Tienter, Dennis, Thompson, Michael A. , Kossick, Kimberlee , Krueger, Eugene W., Kalari, Krishna R., Hawkins, Kaitlyn R., Edwards, Brian S. , Alcaino, Constanza, Guo, Chun‐Jun , Druliner, Brooke R., Ördög, Tamás , Farrugia, Gianrico , Kashyap, Purna , Louwies, Tijs, Mars, Ruben A T, Mercado-Perez, Arnaldo, Bellampalli, Shreya S , Stark Quiroz, Alejandro , Liu, Rongfang , Thompson, Michael A , Kossick, Kimberlee , Lee, Jeong-Heon , van der Es, Daan , Willett, Julia L E , Wongkrasant, Preedajit , Prakash, Y S , Ordog, Tamas , Farrugia, Gianrico , Beyder, Arthur , Smith-Edwards, Kristen M , Kashyap, Purna C , Louwies, Tijs , Mars, Ruben A. , Gupta, Yash , Bhagwate, Aditya , Sekhon, Prabhjot Kaur , Heitman, Laura H. , Krueger, Eugene W. , Lee, Jeong‐Heon , Alcaino, Constanza , Willett, Julia L. E. , Wongkrasant, Preedajit , Prakash, Y. S. , Druliner, Brooke R. , Beyder, Arthur

Mayo Clinic

Proceedings of the National Academy of Sciences | August 24, 2026 | Volume: 123 | Issue: 35 | Pages: No page available

10.1073/pnas.2533336123 | PMID 42636369 Get It

The intestinal epithelium is exposed to diverse combinations of microbiota-derived compounds; however, the mechanisms by which the host integrates these signals remain poorly defined. Studying two highly abundant microbial metabolites, we identified the purine metabolite hypoxanthine as an effector metabolite that directly drives signaling and the short-chain fatty acid butyrate as a regulatory metabolite that conditions host responsiveness. Specifically, hypoxanthine activates the adenosine A1 receptor–TRPC4 axis in enterochromaffin (EC) cells, triggering calcium influx and serotonin release resulting in accelerated gastrointestinal transit locally and increased platelet activation systemically. In contrast, butyrate epigenetically upregulates specific G protein–coupled receptors and ion channels to enhance response to hypoxanthine and the neurotransmitters norepinephrine and dopamine. These findings define a cooperative signaling framework and highlight the role of EC cells as a distinct epithelial signaling hub that senses and integrates microbial metabolite signals to drive physiological responses. Our findings provide a mechanistic foundation for therapeutic strategies that leverage combinatorial microbial signaling.
A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
Choudhury, Atish D. , Zhong, Caiwei , Xie, Wanling , Kochupurakkal, Bose , Wu, Peter I-Fan , Riaz, Irbaz Bin , Liu, Ruolin , Yang, David D. , Folefac, Edmund , Lee, Daniel , McKay, Rana R. , Pace, Amanda F. , Adalsteinsson, Viktor A. , Kunos, Charles A., Gore, Steven D. , Das, Biswajit , Taplin, Mary‐Ellen , Kochupurakkal, Bose S , Parikh, Mamta , Einstein, David J , Kessler, Elizabeth , Mayer, Tina , McKay, Rana R , Pace, Amanda , Mouw, Kent W , Chen, Li , Adalsteinsson, Viktor A , Van Allen, Eliezer M , Kunos, Charles , Gore, Steven D , Das, Biswasjit , D'Andrea, Alan , Taplin, Mary-Ellen , Shapiro, Geoffrey I , Choudhury, Atish D , Riaz, Irbaz B , Xie, Wanling , Wu, Peter I-Fan , Mouw, Kent W. , D’Andrea, Alan D. , Shapiro, Geoffrey I.

Mayo Clinic

Cancer Research Communications | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/2767-9764.crc-26-0488 | PMID 42636061 Get It

Abstract Purpose: Inhibitors of the Ataxia telangiectasia and Rad3-related (ATR) protein kinase, a critical component of the DNA damage repair response, have synergistic anti-cancer activity with platinum compounds in preclinical models. We therefore conducted a Phase 2 study of the ATR inhibitor berzosertib+carboplatin vs. docetaxel+carboplatin in metastatic castration-resistant prostate cancer. Patients and Methods: Patients previously treated with at least one androgen receptor pathway inhibitor and taxane underwent mandatory biopsy and were randomized 1:1 to receive Arm A (docetaxel 60 mg/m2+carboplatin AUC4 day 1; or carboplatin AUC5 if not a docetaxel candidate) or Arm B (berzosertib 90 mg/m2 days 2,9+carboplatin AUC5 day 1) every 21 days. The primary endpoint was overall response rate (ORR; ≥50% PSA decline or radiographic response). Results: Of 73 randomized patients, 65 received protocol treatment: 34 on Arm A (26 docetaxel+carboplatin; 8 carboplatin alone) and 31 on Arm B. Thirteen patients (38%) in Arm A and 20 (65%) in Arm B had ≥Grade 3 treatment-related adverse events (TrAEs). ORR was 15% in Arm A (5/34; 5/26[19%] with docetaxel+carboplatin) and 0% in Arm B (0/31). At interim analysis after 65 of planned 130 patients were treated, enrollment was halted due to futility. Homologous recombination repair deficiency status from tissue and blood did not correlate with clinical outcomes, but ATM-deficiency or high levels of phoshpo-KAP1 detected in tissue was associated with clinical benefit across both arms of the trial. Conclusions: Berzosertib+carboplatin demonstrated lower ORR and more frequent ≥grade 3 TrAEs compared to docetaxel+carboplatin in this heavily pre-treated, biomarker-unselected population. NCT03517969
TDP-43–Associated Neurodegenerative Disease Conceptualization and Integrated Staging
Benatar, Michael, Lagier‐Tourenne, Clotilde , Gregory, Jenna, Al-Chalabi, Ammar, Boeve, Bradley F., Maragakis, Nicholas J., Wuu, Joanne, Zeier, Zane, Onyike, Chiadi, Lewcock, Joe, Hovinga, Collin, Jafar-nejad, Paymaan, Uspenskaya, Olga, Simmons, Adam, Browne, Susan E., Rohrer, Jonathan, Petrucelli, Leonard, Shapiro, Jacquelyn, Scharper, Deb, Boxer, Adam, Staffaroni, Adam M. , Dacks, Penny, Dave, Kuldip D. , Majo, Martina de, Mitic, Laura, Fradette, Stephanie , Haeberlein, Samantha Budd , Simuni, Tanya, Dunn, Billy, Lee, Edward B., Js, Gregory , Benatar, Michael, Barmada, Sami, Jicha, Gregory A. , Al‐Chalabi, Ammar , Boeve, Bradley F. , Jack, Clifford R. , Seeley, William W. , Maragakis, Nicholas J. , Wuu, Joanne , Zeier, Zane R. , Hovinga, Collin A. , Jafar‐Nejad, Paymaan , Uspenskaya, Olga, Simmons, Adam, Browne, Susan E. , Petrucelli, L, Ostrow, Lyle W. , Dacks, Penny A. , Turner, Martin R. , Majo, Martina de , Simuni, Tanya , McMillan, Corey T. , Lee, Edward B.

Mayo Clinic

JAMA Neurology | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.2812 | PMID 42636000 Get It

Importance Classifying disease based on underlying pathobiology rather than clinical phenotype has implications for the development of biomarkers and therapy development. Observations Transactive response DNA-binding protein 43 kDa (TDP-43) pathology is observed across a range of clinically defined neurodegenerative disorders including limbic predominant age-related encephalopathy (LATE), most cases of amyotrophic lateral sclerosis (ALS), inclusion body myositis, multisystem proteinopathy, and approximately half the cases of frontotemporal dementia (FTD). Despite this shared biology, the current nosology for these neurodegenerative disorders is based on their distinct clinical phenotypes. An alternative approach recognizes the central role of TDP-43 pathology in disease pathogenesis, reserving the use of clinical terms like ALS, FTD, or LATE to describe phenotypic manifestations of underlying pathobiology. This approach also recognizes the converging biomarker and neuropathological data indicating that pathology begins presymptomatically, before the overt clinical manifestations of disease appear. Conclusions and Relevance In proposing a pathobiological definition of disease, the goal is to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.
Performance of general-population breast cancer risk prediction models in an international consortium
Brantley, Kristen D. , Ahearn, Thomas U, Norton, Emily , MacInnis, Robert, Palmer, Julie R, Vachon, Celine M, Beane-Freeman, Laura, Frost, Reuben, Zirpoli, Gary, Neuhouser, Marian L, Barnett, Matthew, Teras, Lauren R, Patel, Alpa V, Bodelon, Clara, Spielfogel, Emma S. , Kirsh, Victoria A. , Langseth, Hilde , Milne, Roger L, Haiman, Christopher, Scott, Christopher G, Eliassen, A. Heather, Rosner, Bernard, Willett, Walter C, Chen, Yu, Wu, Fen , Zheng, Wei, Long, Jirong, O'Brien, Katie M, Sandler, Dale P, Linet, Martha S. , Anderson, Garnet, Larson, Joseph C. , Lee, I-Min, Chatterjee, Nilanjan, Kraft, Peter, Brantley, Kristen D , Kirsh, Victoria A , Ahearn, Thomas U. , Norton, Emily L., Palmer, Julie R. , Fortner, Renée T. , Vachon, Celine M. , González, Amy Berrington de , Bertrand, Kimberly A. , Zirpoli, Gary , Barnett, Matthew J , Teras, Lauren R. , Hodge, James M. , Patel, Alpa V , Bodelón, Clara , Lacey, James V. , Rohan, Thomas E. , Tsuruda, Kaitlyn M. , Milne, Roger L , Rosner, Bernard, Willett, Walter C. , Romanos-Nanclares, Andrea , Zheng, Wei , Long, Jirong, O’Brien, Katie M. , Sandler, Dale P. , Kitahara, Cari M. , Anderson, Garnet L. , Lee, I-Min, García‐Closas, Montserrat , Chatterjee, Nilanjan

Mayo Clinic

No container title available | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.20.26360899 Get It

Background: Several breast cancer (BC) risk prediction models have been developed to provide personal risk assessments. Though individually validated, their performance has not been systematically evaluated across a wide range of populations or ages. Methods: We harmonized individual-level baseline questionnaire data and incident BC diagnoses from 21 cohorts from North America, Europe, and Australia participating in the Breast Cancer Risk Prediction Project. Five-year absolute risk of invasive BC was estimated for five established risk prediction models using classical risk factors only. Discrimination was evaluated by area under the curve (AUC). Calibration was assessed using average and risk-decile specific expected to observed (E/O) ratios. Performance metrics were meta-analyzed across cohorts and models. Metaregression tested associations between cohort characteristics and performance metrics. Results: This analysis included 1,595,977 women aged 20-75 years, enrolled in studies between 1976-2015, with 19,062 (1.2%) invasive BC cases ascertained within 5 years from exposure assessment. Age-adjusted AUCs were similar across models and cohorts (pooled AUCs by model: 0.57-0.58), while E/O ratios varied substantially (pooled E/O ratios by model: 0.83-1.25). Overestimation was common among predicted high-risk individuals (>3%). No appreciable differences in model performance by cohort age, birth year, race, and variable missingness emerged. Calibration improved after assigning race-specific incidence rates. Conclusion: Existing BC risk prediction models provided similar risk discrimination across multiple cohorts, although there was overestimation of risk for high-risk individuals. Performance variation across cohorts was not driven by specific characteristics, which supports development of a unified risk model for diverse populations that leverages appropriate incidence rates.
Ethanol reshapes FFC-driven steatohepatitis through time-dependent fibrosis and lipid-droplet remodeling
Weninger, Jasmin , Lee, Amani L. , Marek, George , Lange, Naomi F. , Mauer, Amy S. , Puri, Gyanendra, Shah, Vijay H. , Malhi, Harmeet , Lee, Amani , Marek, George W , Lange, Naomi , Malhi, Harmeet

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | August 22, 2026 | Volume: 331 | Issue: 4 | Pages: G399-G413

10.1152/ajpgi.00223.2026 | PMID 42631413 Get It

This study presents a refined murine MetALD model designed to distinguish ethanol-modified features from FFC-driven metabolic steatohepatitis. Chronic ethanol did not uniformly worsen liver injury. Instead, it selectively modified disease trajectory through greater early collagen-positive fibrotic remodeling, altering lipid-droplet architecture, and context-dependent inflammatory chemokine signaling. By 24 wk, FFC and FFC/ethanol injury programs converged, supporting MetALD as a timing- and pathway-dependent modification of metabolic steatohepatitis.
NF1 Leucine Rich Domain‐Derived Extracellular Vesicles Remodel the Glioblastoma Immune Microenvironment via an ADAM17‐Associated Inflammatory Program
Vijayanathan, Yuganthini , Yeo, Jacqueline YT, Tan, Jiacong , Mohamed, Fikri Bin , Lee, Bernett , Halim, Nurashikin Abdul , Ho, Rachel LY, Zhang, Zhi Wei, Zeng, Li , Tan, Janice Hy , Halim, Nurashikin Abdul , Tu, Hai Tao , Sarkaria, Jann N , Zeng, Li , Ginhoux, Florent , Ho, Ivy Aw , Yeo, Jacqueline Y. T., Kozaki, Tatsuya , Ho, Rachel L. Y., Sarkaria, Jann N.

Mayo Clinic

Journal of Extracellular Vesicles | August 21, 2026 | Volume: 15 | Issue: 8 | Pages: No page available

10.1002/jev2.70355 | PMID 42627929 Get It

ABSTRACT Extracellular vesicles (EVs) are increasingly recognized as mediators of intercellular communication in cancer. We previously demonstrated that re‐expression of the leucine‐rich domain (LRD) of neurofibromin (NF1) suppresses glioblastoma (GBM) invasion and limits microglia/macrophage infiltration into the tumor microenvironment (TME). Given the central role of tumor‐associated microglia/macrophages (TAMs) in GBM progression, we investigated whether NF1‐LRD‐containing EVs (NF1‐LRD‐EVs) could modulate TAM function and remodel the TME. Our results showed that NF1‐LRD‐EVs attenuated microglia and macrophage recruitment in migration assays, consistent with reduced microglia/macrophage recruitment observed in vivo . In parallel, treatment with NF1‐LRD‐EVs enhanced phagocytic activity of both microglia and iPSC‐derived macrophages, accompanied by induction of pro‐inflammatory cytokines TNF‐α, IL‐6, and IL‐1β, and downregulation of immunosuppressive mediators such as Arginase‐1 and IL‐10. Mechanistically, NF1‐LRD‐EVs induced ADAM17‐associated inflammatory signaling, accompanied by NF‐κB activation. Pharmacological inhibition of ADAM17 reduced TNF‐α release and attenuated NF‐κB activation, supporting a role for ADAM17‐dependent signaling in amplifying this inflammatory response. Together, these findings show that NF1‐LRD‐EVs reprogram TAMs toward a pro‐inflammatory phenotype and modulate the GBM immune microenvironment. These results provide a framework for understanding NF1‐LRD‐EV‐mediated immune regulation and support further investigation of EV‐mediated immune modulation of the TME.
Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Adjuvant Therapy for Resected Adenocarcinoma of the Pancreas
Jethwa, Krishan R., Newman, Neil, Selfridge, J. Eva, Anker, Christopher J., Abood, G., Akselrod, Dmitriy, Attallah, Joseph, Hallemeier, Christopher L., Jin, Zhaohui, Kim, Ed, Kennedy, Timothy, Lee, Percy, Ling, Diane C., Miller, Eric D, Sharma, Navesh, Small, William, Tchelebi, Leila, Russo, Suzanne , Jethwa, Krishan R. , Newman, Neil B. , Anker, Christopher J. , Abood, Gerard, Akselrod, Dmitriy , Hallemeier, Christopher Leigh , Hassett, Leslie C. , Lee, Percy, Small, William , Tchelebi, Leila T.

Mayo Clinic

American Journal of Clinical Oncology | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/coc.0000000000001347 | PMID 42622289 Get It

Objectives: Rates of locoregional recurrence and distant metastases are high following curative-intent resection for patients with localized pancreatic adenocarcinoma. Adjuvant therapies have been investigated with the intent to reduce the risk of recurrence and improve OS. The objective of this study is to update and summarize the current evidence for adjuvant therapy following surgical resection for nonmetastatic PDAC with a focus on high-level evidence and randomized controlled trials is provided. Methods: This multispecialty-led committee included gastrointestinal radiation and medical oncology, gastroenterology, radiology, and surgical oncology. Using the population, intervention, comparator, outcome, timing and study design framework, evidence regarding treatment outcomes was assessed using Cochrane and PRISMA methodology. Eligible studies included prospective and retrospective (n≥25) studies published between January 1, 2013 and February 13, 2026, from Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Database of Systematic Review, and Scopus databases. Study type and quality were assessed. Well-established RAND/UCLA consensus methodology (modified Delphi) was used to rate the appropriateness of the treatment options. Results: Of the 74 references used as evidence, 74 are categorized as therapeutic references. Study type and quality for the references were assessed, and included 31 well-designed studies (phase II randomized and phase III), 14 moderately well-designed studies that account for most common biases (matched cohort and phase II studies), 28 studies with design limitations (retrospective reviews), and 1 reference meta-analysis. Conclusions: This systematic review and guidelines provide up-to-date recommendations focusing on recent advancements for adjuvant treatment of resected PDAC using modern systemic therapy regimens and selective use of radiotherapy using modern techniques.